ArticleScience translational medicine2011
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Kimio Yonesaka et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
345 papers cite itlatest 60 shown
this paperpooled ittrialcites it